202 related articles for article (PubMed ID: 28700465)
1. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials.
Zheng J; Song W
Medicine (Baltimore); 2017 Jul; 96(28):e7151. PubMed ID: 28700465
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
Morgan RD; O'Callaghan JM; Knight SR; Morris PJ
Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659
[TBL] [Abstract][Full Text] [Related]
4. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
5. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
[TBL] [Abstract][Full Text] [Related]
6. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review.
Zhang X; Huang H; Han S; Fu S; Wang L
Transpl Immunol; 2012 Oct; 27(2-3):63-8. PubMed ID: 22960043
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
9. [Safety and efficacy of preoperative induction therapy using a single high dose ATG-F in renal transplantation: a meta-analysis of randomized controlled trials].
Yin H; Xu Y; Zhang Q; Xue WR; Zhang ZJ; Zeng S; Hu XP
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1773-7. PubMed ID: 27356647
[TBL] [Abstract][Full Text] [Related]
10. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis.
Liu Y; Zhou P; Han M; Xue CB; Hu XP; Li C
Transplant Proc; 2010 Jun; 42(5):1667-70. PubMed ID: 20620496
[TBL] [Abstract][Full Text] [Related]
11. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction
.
Descourouez JL; Jorgenson MR; Parajuli S; Mandelbrot DA; Leverson GE; Odorico JS; Redfield RR
Clin Nephrol; 2020 Feb; 93(2):77-84. PubMed ID: 31670651
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
15. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
Saull HE; Enderby CY; Gonwa TA; Wadei HM
Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
[TBL] [Abstract][Full Text] [Related]
16. Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates.
Shamsaeefar A; Roozbeh J; Khajerezae S; Nikeghbalian S; Kazemi K; Motazedian N; Geramizadeh B; Malekhosseini SA
Saudi J Kidney Dis Transpl; 2016; 27(4):665-70. PubMed ID: 27424681
[TBL] [Abstract][Full Text] [Related]
17. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]